{
  "clinical_research_data": {
    "literature_search_results": [
      {
        "title": "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer",
        "authors": ["Conroy T", "Desseigne F", "Ychou M", "et al."],
        "journal": "New England Journal of Medicine",
        "year": 2011,
        "pmid": "21561347",
        "doi": "10.1056/NEJMoa1011923",
        "study_type": "Randomized Controlled Trial",
        "patient_population": "Metastatic pancreatic adenocarcinoma",
        "intervention": "FOLFIRINOX vs Gemcitabine",
        "primary_endpoint": "Overall survival",
        "key_findings": [
          "Median OS: 11.1 vs 6.8 months (HR 0.57, p<0.001)",
          "Median PFS: 6.4 vs 3.3 months (HR 0.47, p<0.001)",
          "Response rate: 31.6% vs 9.4% (p<0.001)",
          "Higher toxicity with FOLFIRINOX"
        ],
        "relevance_score": 0.95,
        "evidence_level": "1A"
      },
      {
        "title": "Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Adenocarcinoma",
        "authors": ["Von Hoff DD", "Ervin T", "Arena FP", "et al."],
        "journal": "New England Journal of Medicine",
        "year": 2013,
        "pmid": "24094212",
        "doi": "10.1056/NEJMoa1304369",
        "study_type": "Randomized Controlled Trial",
        "patient_population": "Metastatic pancreatic adenocarcinoma",
        "intervention": "Nab-paclitaxel + Gemcitabine vs Gemcitabine",
        "primary_endpoint": "Overall survival",
        "key_findings": [
          "Median OS: 8.5 vs 6.7 months (HR 0.72, p<0.001)",
          "1-year survival: 35% vs 22%",
          "Response rate: 23% vs 7% (p<0.001)",
          "Manageable toxicity profile"
        ],
        "relevance_score": 0.92,
        "evidence_level": "1A"
      },
      {
        "title": "KRAS G12C Inhibitor AMG 510 in Advanced Solid Tumors",
        "authors": ["Hong DS", "Fakih MG", "Strickler JH", "et al."],
        "journal": "New England Journal of Medicine",
        "year": 2020,
        "pmid": "32955176",
        "doi": "10.1056/NEJMoa2002787",
        "study_type": "Phase I/II Trial",
        "patient_population": "KRAS G12C-mutant solid tumors",
        "intervention": "AMG 510 (Sotorasib)",
        "primary_endpoint": "Safety and efficacy",
        "key_findings": [
          "Overall response rate: 32.2% in NSCLC",
          "Disease control rate: 88.1%",
          "Median duration of response: 11.1 months",
          "Generally well tolerated"
        ],
        "relevance_score": 0.78,
        "evidence_level": "2A",
        "notes": "Limited data for pancreatic cancer with KRAS G12D"
      }
    ],
    "treatment_guidelines": [
      {
        "organization": "NCCN",
        "guideline": "Pancreatic Adenocarcinoma",
        "version": "2025.1",
        "recommendations": [
          {
            "category": "First-line metastatic",
            "performance_status": "ECOG 0-1",
            "regimens": [
              "FOLFIRINOX (preferred)",
              "Gemcitabine + nab-paclitaxel",
              "Gemcitabine monotherapy (if not candidate for combination)"
            ]
          },
          {
            "category": "Second-line metastatic",
            "prior_therapy": "Gemcitabine-based",
            "regimens": [
              "5-FU + liposomal irinotecan + leucovorin",
              "5-FU + oxaliplatin"
            ]
          }
        ]
      },
      {
        "organization": "ESMO",
        "guideline": "Pancreatic Cancer Clinical Practice Guidelines",
        "version": "2024",
        "recommendations": [
          {
            "category": "Systemic therapy",
            "evidence": "Grade A",
            "recommendation": "FOLFIRINOX or gemcitabine + nab-paclitaxel for fit patients"
          },
          {
            "category": "Biomarker testing",
            "evidence": "Grade B",
            "recommendation": "Test for BRCA1/2, MSI, and homologous recombination deficiency"
          }
        ]
      }
    ],
    "prognostic_factors": [
      {
        "factor": "Performance Status",
        "description": "ECOG 0-1 vs 2+",
        "hazard_ratio": 1.8,
        "confidence_interval": "1.4-2.3",
        "p_value": "<0.001"
      },
      {
        "factor": "CA 19-9 level",
        "description": ">1000 vs <100 U/mL",
        "hazard_ratio": 2.1,
        "confidence_interval": "1.6-2.7",
        "p_value": "<0.001"
      },
      {
        "factor": "Number of metastatic sites",
        "description": "â‰¥3 vs 1-2 sites",
        "hazard_ratio": 1.6,
        "confidence_interval": "1.2-2.1",
        "p_value": "0.002"
      }
    ]
  },
  "clinical_trials_matching": [
    {
      "nct_id": "NCT04185883",
      "title": "KRAS G12C Inhibitor in Advanced Solid Tumors",
      "phase": "Phase II",
      "status": "Recruiting",
      "location": "Multiple centers",
      "eligibility_criteria": [
        "KRAS G12C mutation confirmed",
        "Advanced solid tumor",
        "ECOG PS 0-1",
        "Adequate organ function"
      ],
      "primary_endpoint": "Overall response rate",
      "estimated_enrollment": 300,
      "match_score": 0.65,
      "exclusion_reason": "Patient has KRAS G12D, not G12C"
    },
    {
      "nct_id": "NCT03768414",
      "title": "Pancreatic Cancer Precision Medicine Trial",
      "phase": "Phase II",
      "status": "Recruiting",
      "location": "Johns Hopkins, Mayo Clinic, MSKCC",
      "eligibility_criteria": [
        "Metastatic pancreatic adenocarcinoma",
        "Molecular profiling completed",
        "Prior systemic therapy allowed",
        "ECOG PS 0-2"
      ],
      "primary_endpoint": "Progression-free survival",
      "estimated_enrollment": 200,
      "match_score": 0.89,
      "match_criteria": [
        "Disease type: Perfect match",
        "Stage: Perfect match",
        "Prior therapy: Eligible",
        "Performance status: Eligible"
      ]
    },
    {
      "nct_id": "NCT04390763",
      "title": "Immunotherapy Combination in Pancreatic Cancer",
      "phase": "Phase I/II",
      "status": "Active, not recruiting",
      "location": "University of California centers",
      "eligibility_criteria": [
        "Pancreatic adenocarcinoma",
        "Measurable disease",
        "No active autoimmune disease",
        "ECOG PS 0-1"
      ],
      "primary_endpoint": "Safety and tolerability",
      "estimated_enrollment": 150,
      "match_score": 0.72,
      "match_criteria": [
        "Disease type: Perfect match",
        "Measurable disease: Yes",
        "Performance status: Eligible"
      ]
    }
  ]
}
